Group items tagged

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

The Pharmaceutical Services Negotiating Committee (PSNC) has announced that the new Pharmacy Quality Scheme (PQS) for this year will officially begin on October 10. From previous scheme £75m funding is also available and contractors will be able to claim an 'Aspiration payment' if they wish to, later this year. PSNC, the Department of Health and Social Care and NHS England have agreed the arrangements for the 2022/23 PQS, as well as those for the 2023/24 PQS, with a focus on supporting recovery from Covid-19 and wider national health priorities. The committee said: "In our negotiations on the scheme, PSNC has managed to reduce the scope of this year's PQS so that the estimated contractor costs and time required to complete the criteria will be below those associated with the original NHS proposals for the scheme." "A further reduction in scope has also been agreed due to the delayed start of the 2022/23 PQS. PSNC hopes that this, along with arguing for more realistic targets across the scheme, will help reduce the impact on contractor workload, at what continues to be a very busy and pressured period for the sector."

Lo's Pharmacy, a Yorkshire-based pharmacy chain is adopting a new approach to hub and spoke in a first of a kind model to be used in the UK. The pharmacy will centralise its repeat prescription dispensing service for original packs with the support of its medication wholesaler. The independent group, which has 25 NHS community pharmacies across Yorkshire, will install Centred Solution's Automated FLOWRx Hub product at its central dispensing facility in Wath-Upon-Dearne, South Yorkshire. But unlike other FLOWRx customers, who pick packs from a robotic dispensing system or internal warehouse, Lo's Pharmacy will receive patient-specific flow totes directly from their wholesaler which can then be processed by their hub. This workflow has not been used anywhere else in the country until now and it is a revolutionary approach to hub and spoke dispensing, showing what can be achieved when key players decide to collaborate. It further demonstrates that there are range of variations of hub and spoke models available and accessible to independent and multiple community pharmacies across the UK.

Professional translators recreate texts, not simply matching word-for-word, but understanding the underlying meaning, purpose, and interpretation of the original language, and reproduce it using appropriate terminology and structure to ensure there is no potential for misunderstanding. An experienced technical translator addresses conventions to ensure the meaning of the information is preserved, using medical expertise and quality review processes to adapt documentation to meet the needs of patients, medical practitioners, and peers. Attention to detail is fundamental to medical translations and a non-technical translation is an unacceptably high risk for any organisation involved in publishing or circulating medical information of any kind. WHAT IS MEDICAL TRANSLATION? Medical translation is a technical process where capable translators reproduce content or documentation used anywhere in the medical industry, including psychiatry, systematic reviews, tuition and training, patient communications for pharmaceutical translation services. Important clinical trial translations can include labelling, prescriptions, medical devices and patient records, with millions of medicines and treatments used globally and written in multiple languages. Qualified medical translators must have exceptional linguistic skills but also a thorough understanding of medical sciences in all the native languages concerned. However, the complexity of translating one label or one document into several languages can mean that organisations may assume a simple translation is sufficient - when it is anything but!

The Department of Health and Social Care (DHSC) has extended the Serious Shortage Protocols (SSPs) for Fluoxetine 10mg tablets (SSP005) and Lipitor 10mg chewable tablets (SSP032) to Wednesday, 7 December 2022. SSP005 for Fluoxetine 10mg tablets was due to expire on 12 August 2022. DHSC has also updated that SSP032 for Lipitor 10mg chewable tablets was due to expire on 12 August 2022 but the end date has been further extended to Friday 26 August 2022. SSP005 provides that for every Fluoxetine 10mg tablet originally prescribed, one Fluoxetine 10mg capsule must be supplied: "Expiry dates of an SSP may be brought forward or extended, and the content may be amended at any time during the life of an SSP. Pharmacists should ensure they are using the latest version of an SSP before considering the supply of an alternative product," said DHSC.

The Department of Health and Social Care (DHSC) has issued two new Serious Shortage Protocols (SSPs) for Estraderm MX 25mcg and 100mcg patches. Effective from 8 September 2022, SSP035 and SSP036 provide that for every Estraderm MX 25mcg or 100mcg patch originally prescribed, one Evorel 25mcg patch or 100mcg patch must be supplied, respectively. Both SSPs are currently set to expire on 16 September 2022. Both SSPs, authorised by the secretary of state for health, have been developed by clinicians and provides pharmacists with procedures to follow in providing either of these suitable alternative products to help reduce the number of patients having to return to their prescriber for a replacement prescription. DHSC informed that there are no SSPs in place for Estraderm MX 50mcg patches and 75mcg patches - these strengths are not affected by supply disruptions and should continue to be dispensed in accordance with the prescriptions "The SSP035 and SSP036 only allow substitution of Estraderm MX 25 or 100 patches with Evorel 25 or 100 patches, respectively."

The Pharmacists' Defence Association (PDA) has welcomed the Westminster government's move to backtracked from their plan to remove a large number of rights and standards and is having to overhaul the Retained EU Law Bill. This had included a number of employment rights, including TUPE transfers and the Working Time Directive, which had been established in the UK from EU law. The Bill's 'sunset clause' was originally going to automatically repeal any EU law not enshrined in UK law by the end of 2023. Critics of the Bill were concerned that this gave the government powers to reform or remove laws without normal Parliamentary scrutiny. "This would have abolished many improvements to workers' rights which were enacted through the EU legislature," said PDA.

The Community Pharmacist Consultation Service (CPCS) will be expanded to enable urgent and emergency care settings to refer patients to a community pharmacist for a consultation for minor illness or urgent medicine supply from Monday (15 May), the DHSC and NHSE said. The service builds on the progress made in GP referrals via the CPCS and hospital referrals under the Discharge Medicine Service. It was originally planned to launch in March, and fee for this service will be the existing CPCS fee of £14, as per the agreement for both year 4 and year 5 of the Community Pharmacy Contractual Framework (CPCF) 2019 to 2024 5-year deal. In an update on the CPCF, published today (12 May), the Department of Health and Social Care (DHSC) and NHS England (NHSE) has also committed to the 4 October 2023 launch date for the Tier 2 of the Pharmacy Contraception Service, subject to a positive evaluation of the pilot. The Tier 1 of the service was launched on 24 April, delayed by over three months. This new service enables community pharmacists to provide ongoing management, via a patient group direction (PGD), of routine oral contraception that was initiated in general practice or by a sexual health clinic. The fees for this service are as follows: a fee for each consultation of £18; and a set-up fee of £900, paid in instalments. The Tier 2 will "enable community pharmacists to also initiate oral contraception, via a PGD, and provide ongoing clinical checks and annual reviews," Alette Addison, deputy director for pharmacy, dental and optical at the DHSC and Ali Sparke, director for dentistry, community pharmacy and optometry at the NHSE, said in a letter.

Bladder leakage is one of the most common healthcare issues affecting women, with the effects of the condition having major effects on women's lives. 1 in 3 women over the age of 18 experience bladder leakage at some point in their lives,1 and in general, prevalence increases at the start of the menopause. It is a major taboo and due to embarrassment women sometimes struggle to discuss the condition and need help. It is now time for community pharmacy teams to take the lead and provide the proactive support your customers need - and don't just reach for the pads…. You can help them stop the leaks, and build customer loyalty. If women are regularly buying pads, or have struggled with using pharmacological solutions you can now offer alternative approaches. What is incontinence? Urinary incontinence is when a person accidentally passes urine when they don't want to. It occurs when their bladder is put under pressure, such as when they cough, sneeze, laugh or run. Frequent or occasional, it can vary from a few dribbles to a complete loss of bladder control. There are several known types of bladder and urinary incontinence. They receive their name from the origin of the issue that causes the passing of urine. Although they are similar and can have some of the same symptoms, they mostly differ in the way they come about: Stress urinary incontinence (SUI) - causes the leak after a person strains or exerts themselves during a physical activity, including coughing, sneezing, laughing, running or jumping. This is the most common type of urinary incontinence.

Community Pharmacy England (CPE) is aiming to reach an agreement with the Department of Health and Social Care (DHSC) and NHS England (NHSE) on negotiation with regards to expanded services and payment model in the pharmacy sector. Chief Executive Janet Morrison, said: "We are working at pace in negotiations with DHSC and NHSE. The process remains on track with the Government's original timescale - i.e. aiming for agreement in July, with cross-government clearance later in July, and implementation from July through to September." CPE is involved in working groups on service expansion of Hypertension Case-Finding and the Pharmacy Contraception Scheme and service design for the Common Conditions Service; and are in in-depth negotiations on Payment models. These discussions critically look at the balance between funding core capacity and activity payments, how the funding streams will be distributed and how CPE will measure delivery and impact. NHSE has been leading on the development of the PGD pathways for each of the 7 conditions, with external medical, pharmacy and other experts feeding into the process - pharmacy owners from the Community Pharmacy England Committee have also been involved but the discussions are clinically led to ensure they comply with NICE principles and concur with Antimicrobial Stewardship policy.

The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price. The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel disease and psoriasis, has accounted for about one third of the savings. After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions, which have the same quality, safety and efficacy of a branded one. Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to aggressive blood cancers. Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality patient care. NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.

Dental procedures are a necessary evil for most people. We all know that we need to go in for a cleaning and check-up at least once a year, but sometimes the cost of these procedures can be prohibitive. It's hard to know which procedures are worth the money and which ones aren't. Here is an essential list of dental procedures that are worth the money. CAVITY FILLINGS Cavities are caused by tooth decay. If left untreated, cavities can cause severe damage to your teeth. They can also lead to pain and infection. The best way to treat a cavity is to have it filled by a dentist. During the procedure, your dentist will remove the decay from your tooth and then fill the cavity with a composite material. This material is solid and durable and can help restore your tooth to its original shape and function. Modern materials and techniques have made cavity fillings much more effective than they used to be. Most fillings last for many years with proper care. ROOT CANALS It's a dental procedure that is used to treat an infected tooth. During the procedure, the dentist will remove the infected tissue from the tooth and then fill the space with a particular material. The procedures are very effective in treating infected teeth. They can also help to prevent the spread of infection to other teeth. Root canals are usually very successful, and most teeth with a root canal can last for many years. Generally, the cost of the procedure will depend on the severity of the infection and the number of teeth that need to be treated. If you are considering treatment for a root canal, it is crucial to find a qualified and experienced dentist who has experience. You want a team that assures you of world-class standards in all their procedures. This is what brings you value for your money.

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

The British Generic Manufacturers Association (BGMA) has elected Matthew Salzmann, UK Country Manager at Viatris, as its new Vice-Chair with immediate effect. He will replace the current chair of the BGMA, Diane DiGangi-Trench, who is the UK country head for Sandoz. Salzman, who is originally from Australia, has served approximately 1 billion patients worldwide last year as the UK Country Manager at Viatris, a global pharmaceutical company operating in 165 countries. In his role as BGMA Vice-Chair, Salzmann would focus on working in partnership with key stakeholders - the NHS, healthcare professionals, policy makers, clinical societies, patient associations, academia - to ensure access to affordable and sustainable medicines for patients and the NHS.

Travelling with medical cannabis can be a complex and often confusing experience, given the diverse legal regulations across different countries and states. Patients who rely on medical cannabis for their wellbeing need to be well-informed and prepared to ensure a smooth and hassle-free travel experience. This comprehensive guide covers essential aspects, legal considerations, and practical tips for individuals who use medical cannabis and wish to travel. Know the Laws The first and most crucial step before travelling with medical cannabis is to understand the laws and regulations of both the departure and destination locations. Laws regarding medical cannabis use vary significantly from one country, state, or even city to another. Some places have legalised medical cannabis, while others strictly prohibit its use. Researching and familiarising oneself with the specific regulations of the destination, transit countries, and the home country is essential. Travelling Within the Same Country When travelling within a country where medical cannabis is legal, patients generally need to carry their prescription information issued by a licensed healthcare provider. It's advisable to keep medical cannabis in its original packaging, clearly labelled with the patient's name, prescribing physician, and dosage instructions. Carrying a copy of the relevant laws and regulations can also be helpful in case of any inquiries from authorities. What can be easier than carrying around paperwork, which could get easily damaged or lost during your travels, is to get a medical card that has a unique QR code on it from Releaf Cannabis, which, when scanned, can present their prescription information digitally - it has revolutionised the way patients manage their healthcare. This eliminates the need for physical documents and streamlines the process but also ensures the security and confidentiality of sensitive medical information, offering patients a more efficient and organi

The Association of Independent Multiple Pharmacies (AIMp) has appointed David Vanns as its non-executive Chairman following the retirement of its long serving Chair Peter Cattee. Vanns will take up the role from April 2023. Cattee, one of the co-founders of AIMp took up the role as its Chairman in 2000. He is also a non-CCA representative on the PSNC. Despite retiring as chairman Cattee will remain on the AIMp board. Commenting on his retirement Cattee said: "It's been my great good fortune to work with almost all of the owners of pharmacy groups throughout England, Scotland and Wales over the years and many other talented people throughout the sector. It's been during a period of increasing consolidation, something which our own business has reflected, and the original founders and Board members Yakub Patel, Kirit Patel, Steve Williams and David Vanns have all been instrumental in shaping pharmacy negotiations to better reflect the views of our natural constituency - pharmacy group owners. A spokesperson for AIMp said: "We thank Peter for his services and dedication to AIMp throughout the years. Our organisation has grown to be a diverse and dynamic organisation representing and supporting pharmacy groups of all sizes, small and large. Our main identity and what unites us in AIMp, irrespective of the size of the pharmacy group, is being Independents, and we are very proud of our identity. We look forward to continuing our work in representing and supporting our members in the best way possible."

The Pharmacists' Defence Association (PDA) is supporting pharmacists in England whose employment has been impacted by the creation of new NHS structures. As a result of the 2022 Health and Care Act, Integrated Care Systems (ICSs) were established in England, and Clinical Commissioning Groups (CCGs) were closed on 1 July 2022. Each of the ICSs includes two key parts: an Integrated Care Board (ICB) and an Integrated Care Partnership (ICP). The association said: "The previous structures in England, established by the Health and Social Care Act 2012, originally had over 200 clinical commissioning groups. This number had reduced over recent years via mergers." "However, this latest shift to just 42 commissioning entities means a significant change to significantly larger geographies and populations covered by each ICS. Although each ICS and its activity can be subdivided into 'places', and within places into 'neighbourhoods', it is at the ICS level that the employer is formed." "Whereas CCGs previously employed many local health professionals, including pharmacists, the new arrangements mean that ICBs are now that employer. The PDA is supporting members who have contacted its Service Centre about the impact of these changes."

The specification for the Pharmacy Contraceptive Service has been launched for pharmacy contractors to download from the NHSBSA website. However, the service will not start on 11th January 2023, as originally planned, but it is expected to commence in early 2023, revealed the Pharmaceutical Services Negotiating Committee (PSNC). It added: "The exact start date is yet to be agreed, as now the service specification has been published, community pharmacy IT system suppliers need time to develop support for the service, so this is available to contractors from the service commencement date." Commenting on the publication of the service specification, Alastair Buxton, Director of NHS Services, at PSNC said: "When time in their busy professional lives allows, the publication of the service specification ahead of the start of the new service provides contractors and their teams with an opportunity to learn more about it and to consider whether it is something they will have the capacity to provide in due course.

Our Totton branch has an incredibly high volume of original pack dispensing, roughly 45,000 items. As we became busier and busier in the dispensary we were finding that our pharmacists, dispensers and other technicians simply didn't have capacity to deliver the services that we needed them to. We all know there is a real emphasis right now on pharmacies doing more services and we knew we had to change the way we operate to survive. So we decided it was time to look into a sound automation solution for our medication dispensing process, one that would allow us to free up the time of the pharmacists and the rest of the team so they could better support patients. After a lot of research we invested in Centred Solutions FLOWRx Hub and InStore solutions which were installed late last year. It provides us with the whole package and has automated our entire dispensing process from picking to packing and labeling to checking. Our situation was quite unique as we bought the system initially for our existing high-volume pharmacy in Totton so the hub and the spoke are actually on the same site. People wouldn't usually look at a hub and spoke solution for that kind of set up but it has allowed us to significantly free up time in store for more services. What it has also done is allow us to look at other opportunities to grow and expand. The pharmacy landscape is changing and there are lots of opportunities coming up. We have found that having your technology and the right infrastructure in place to support your existing footprint before you expand is the ideal way to grow in a safe and controlled way. We never thought that five years ago we would buy another pharmacy, yet we have already bought one and are now in the process of buying two more. I'm not worried about the increase in volume this expansion will bring because I know our technology is going to be able to support it. The pharmacies we are buying are struggling but having our solution already in p

The Royal Pharmaceutical Society (RPS) has updated the Professional Standards for Homecare Services to ensure high quality care for patients receiving medicines and associated services in the comfort of their own homes. Originally published in 2013, these standards provide a comprehensive framework to support teams involved in planning, commissioning, and delivering homecare services. The RPS said that these standards were updated to ensure that they align with the needs and expectations of recipients of homecare services, as well as commissioners and providers. Changes were made based on responses received through a consultation process, which was participated by representatives from the National Homecare Medicines Committee, the Association of Pharmacy Technicians, the Pharmacy Forum of Northern Ireland, and the Royal College of Nursing.